Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | FPR3 | P25089 | 3/20 | 0.34 |
| ▸ | FPR2 | P25090 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1816048 | 0.83 | SLC6A2 (0.44) | HRH3SLC6A2SLC6A4SLC6A3HPGD | |
| SCHEMBL4849081 | 0.83 | SLC6A2 (0.44) | HRH3SLC6A2SLC6A4SLC6A3HPGD | |
| SCHEMBL4800534 | 0.82 | SLC6A2 (0.42) | HRH3SLC6A2SLC6A4SLC6A3CXCR3 | |
| SCHEMBL4847242 | 0.80 | SLC6A2 (0.40) | HRH3SLC6A2SLC6A4SLC6A3L3MBTL1 | |
| SCHEMBL4847243 | 0.80 | SLC6A2 (0.40) | HRH3SLC6A2SLC6A4SLC6A3L3MBTL1 | |
| SCHEMBL14254704 | 0.76 | FPR2 (0.44) | HRH3SLC6A2SLC6A4SLC6A3CXCR3 | |
| SCHEMBL27482371 | 0.72 | MME (0.36) | HRH3SLC6A2SLC6A4SLC6A3CXCR3 | |
| SCHEMBL11234764 | 0.70 | HRH3 (0.56) | HRH3SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL1819135 | 0.70 | HRH3 (0.56) | HRH3SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL10956783 | 0.69 | SLC6A2 (0.56) | HRH3SLC6A2SLC6A4SLC6A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7375237-B2 | Pyrrolizine compounds useful as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-20 | — | — | US | disclosed |
| US-20060052434-A1 | Pyrrolizine compounds useful as anti-inflammatory agents | CEREP S.A. (FR) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052434-A1 | Pyrrolizine compounds useful as anti-inflammatory agents | NFKBIA, TNF, NFKB1 | HRH3 618/4885SLC6A2 4879/4885SLC6A4 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.